Skip to main content

Table 6 Cox regression on retention for monotherapy versus individual combination therapies

From: A pilot trial of quetiapine, lithium, or placebo added to divalproex sodium for hypomanic or manic episodes in ambulatory adults with bipolar I disorder

Variable B SE Wald P Hazard ratio 95% CI
Group
 PBO
 Li 1.11 (1.11) 0.53 (0.52) 2.11 (2.14) 0.035* (0.033) 3.04 (3.04) 1.08–8.57 (1.10–8.43)
 QTP 0.27 (0.17) 0.58 (0.59) 0.46 (0.29) 0.644 (0.773) 1.31 (1.18) 0.42–4.06 (0.38–3.73)
Side effect 0.08 (0.09) 0.11 (0.11) 0.76 (0.78) 0.448 (.435) 1.09 (1.09) 0.88–1.35 (0.88–1.35)
Side effect severity × Li − 0.05 (− 0.04) 0.12 (0.13) − 0.43 (− 0.33) 0.666 (0.742) 0.95 (0.96) 0.75–1.21 (0.75–1.23)
Side effect severity × QTP − 0.03 (− 0.03) 0.11 (0.11) − 0.30 (− 0.29) 0.763 (0.769) 0.97 (0.97) 0.77–1.21 (0.78–1.21)
YMRS 0.00 (0.00) 0.03 (0.03) 0.11 (0.84) 0.914 (0.933) 1.00 (1.00) 0.95–1.06 (0.95–1.06)
HAM-D 0.06 (0.06) 0.04 (0.04) 1.64 (1.59) 0.101 (0.113) 1.06 (1.06) 0.99–1.14 (0.99–1.14)
Site − 0.68 1.06 − 0.64 0.521 0.51 0.06–4.06
  1. Estimates for the model that excluded site are shown in parentheses
  2. PBO: monotherapy divalproex plus placebo; Li: combination therapy of divalproex plus blinded lithium; QTP: divalproex plus blinded quetiapine
  3. “–” indicates reference group
  4. *Significant at p < 0.05